Aurealis Therapeutics Press Releases - EIN Presswire - Press Release Distribution Service

Published on December 4, 2025 - 09:09 GMT

Aurealis Therapeutics DIAMEND Phase-2 RCT: AUP-16 Tripling Complete Wound Closure Rate in Patients with Chronic DFU

Positive Blinded Evaluator Efficacy Results of Aurealis "DIAMEND" Phase-2 RCT, AUP-16 Tripling Complete Wound Closure Rate in Chronic Diabetic Foot Ulcers ZUG, SWITZERLAND, December 4, 2025 /⁨EINPresswire.com⁩/ -- Aurealis Therapeutics, a …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on November 13, 2024 - 10:42 GMT

Aurealis Therapeutics raises CHF 8M to complete Phase-2 studies in Chronic Wounds and accelerate Oncology program

Funds will be used to complete Phase 2 RCTs with AUP-16 for Chronic Wounds, and accelerate the development of AUP-55 for ovarian, peritoneal and bladder cancer. ZUG, SWITZERLAND, November 13, 2024 /⁨EINPresswire.com⁩/ -- Aurealis Therapeutics, a synthetic …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on March 11, 2024 - 14:42 GMT

Aurealis Therapeutics completes 50% patient recruitment for DIAMEND Phase-2 study in Diabetic Foot Ulcers

Half of the patients expected to participate DIAMEND Phase-2 study with AUP-16 in Diabetic Foot Ulcers (DFUs) have now been recruited and randomized. ZUG, SWITZERLAND, March 11, 2024 /⁨EINPresswire.com⁩/ -- Aurealis Therapeutics, a Swiss-Nordic clinical- …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on February 27, 2024 - 13:04 GMT

Aurealis Therapeutics’ lead candidate AUP-16 for chronic wounds receives PRIME status from EMA

Aurealis Therapeutics receives PRIME status from EMA for Enhanced Regulatory Support and Accelerated Assessment of AUP-16 in Non-healing Diabetic Foot Ulcers ZUG, SWITZERLAND, February 27, 2024 /⁨EINPresswire.com⁩/ -- • Priority medicines (PRIME) is a …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on August 8, 2023 - 12:44 GMT

Aurealis Therapeutics Announces First Patient Dosed in DIAMEND Phase 2 Diabetic Foot Ulcer Clinical Trial of AUP-16

BASEL, BASEL-STADT, SWITZERLAND, August 8, 2023 /⁨EINPresswire.com⁩/ -- Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, announced …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on May 9, 2023 - 08:45 GMT

Aurealis Therapeutics receives CTA approval for AUP-16 Phase 2 RCT in Diabetic Foot Ulcer patients

Multi-center, randomized, placebo-controlled diabetic foot ulcer (DFU) Phase 2 study to start May 2023 in Italy, Germany, and Poland BASEL, SWITZERLAND, May 9, 2023 /⁨EINPresswire.com⁩/ -- Aurealis Therapeutics, a Swiss-Finnish private clinical-stage …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Published on March 30, 2023 - 09:00 GMT

Aurealis Therapeutics Raises $10 Million Series A To Drive Multi-Factor Bacterial Vectors in Chronic Wounds and Oncology

BASEL, SWITZERLAND, March 30, 2023 /⁨EINPresswire.com⁩/ -- AUREALIS THERAPEUTICS RAISES $10 MILLION IN AN OVERSUBSCRIBED SERIES A FINANCING TO ACCELERATE PHASE 2 CLINICAL STUDIES IN CHRONIC WOUNDS AND PRECLINICAL DEVELOPMENT IN ONCOLOGY WITH ITS FIRST-IN- …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...